Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials
Abstract The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50–1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80–5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76–3.50]) or 14-day viral (OR 5.37 [95% CI 0.35–83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
SN comprehensive clinical medicine - 2(2020), 8 vom: 15. Juli, Seite 1120-1131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Siordia, Juan A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Arbidol |
|---|
| doi: |
10.1007/s42399-020-00399-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR040584925 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR040584925 | ||
| 003 | DE-627 | ||
| 005 | 20230519105531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42399-020-00399-6 |2 doi | |
| 035 | |a (DE-627)SPR040584925 | ||
| 035 | |a (SPR)s42399-020-00399-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Siordia, Juan A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50–1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80–5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76–3.50]) or 14-day viral (OR 5.37 [95% CI 0.35–83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Coronavirus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Treatment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Trials |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lopinavir/ritonavir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Arbidol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hydroxychloroquine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Remdesivir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tocilizumab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Favipiravir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Heparin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dexamethasone |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Bernaba, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Ulhaque, Abid |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Sooraj |e verfasserin |4 aut | |
| 700 | 1 | |a Bernaba, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Bergin, Edward |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d [Cham] : Springer International Publishing, 2019 |g 2(2020), 8 vom: 15. Juli, Seite 1120-1131 |w (DE-627)SPR038535785 |w (DE-600)2947252-0 |x 2523-8973 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2020 |g number:8 |g day:15 |g month:07 |g pages:1120-1131 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s42399-020-00399-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2020 |e 8 |b 15 |c 07 |h 1120-1131 | ||